This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
 

TRANSFORMATION - Adjuvant Melanoma: Time for Action

Videoconference image
Rate:
 
Rating
 
22nd Mar 201910:00 - 14:30

This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting.
MSD are hosting an event to launch KEYTRUDA ▼(pembrolizumab) for the adjuvant treatment for melanoma following marketing authorisation in the UK.

The meeting aims to explore the progress made in the treatment of melanoma including the opportunities that are now available within the new adjuvant setting.
  • To explore the clinical data that has led to the recent approvals of adjuvant treatments for melanoma, in order to enhance the knowledge and understanding of those involved in the melanoma MDT
  • To discuss the current clinical treatment considerations in the management of adjuvant melanoma patients
  • To raise awareness of the learnings that have been gained from the introduction of adjuvant treatment within other types of cancer (e.g. breast cancer)
KEYTRUDA as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.

KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.

Click here for prescribing information

Attend

Important For Online Events Only:

Click here to test the computer that you will be using to make sure you have the minimum technical requirements to attend this Webcast. Allow sufficient time before the Webcast for this test.

Agenda
Start timeDetails
10:00Welcome and Introduction
Professor James Larkin
10:10The Science of Saving Lives: The past, present and future of immunotherapy research in the UK
Professor Charles Swanton
10:55Putting Theory into Practice: How adjuvant clinical data translates to everyday treatment for melanoma patients
Professor James Larkin
Dr Paul Nathan
Dr Sophie Papa
11:55Break
12:10Case by Case: Putting the patients first – a series of patient case scenarios that highlight the current treatment decisions involved in the management of adjuvant melanoma patients
Professor James Larkin
Dr Paul Nathan
Dr Sophie Papa
Jackie Hodgetts
13:10Break
13:40Patient first: The role of patient advocacy groups within clinical trials and patient education
Simon Rodwell
14:00Transformational Service Changes: Sharing best practice for service optimisation with the introduction of adjuvant therapies
Jackie Hodgetts
Dr Mark Harries
Speakers
Speaker image
Professor James Larkin
Professor James Larkin MA, FRCP, PhD, FMedSci, Consultant Medical Oncologist, The Royal Marsden Hospital London

Read more
Speaker image
Professor Charles Swanton
Professor Charles Swanton, FRCP PhD FMedSci, FRS, Francis Crick Institute London


Read more
Speaker image
Dr Paul Nathan
Dr Paul Nathan, MBBS, PhD, FRCP, Mount Vernon Cancer Centre Northwood


Read more
Speaker image
Dr Sophie Papa
Dr Sophie Papa, MA, MBBS, MRCP, PhD, Guy's and St Thomas' NHS Foundation Trust London


Read more
Speaker image
Jackie Hodgetts
Jackie Hodgetts, Nurse Clinician, The Christie Hospital Manchester
Read more
Speaker image
Simon Rodwell
Simon Rodwell, Chief Executive, Melanoma Focus
Read more
Speaker image
Dr Mark Harries
Dr Mark Harries, MA MB BChir PhD FRCP, Consultant Medical Oncologist, Guy’s & St Thomas’ Hospitals NHS Foundation Trust
Read more

GB-OOC-00078 Date of preparation: February 2019